Functions · BD & licensing

Business Development & Licensing

Time the conversation before the readout. See which assets approach Phase 2/3 completion, where whitespace sits, and what a target really has in its pipeline.

15ranked use cases
#4highest overall rank: Deal timing intelligence
1 clickfrom recipe to a board with the right charts
Lead chart, on real data

What this team sees first.

A timeline shows who reads out when, measured against today. In eosinophilic esophagitis, six of nine active trials reach primary completion in 2026.

Every use case below opens with its signature chart and a recommended set of supporting views, chosen from 91 chart types.

Built for: BD, Corporate Strategy, Corporate Development, Business Development, Competitive Intelligence.

Timeline · EoE primary completionReal data

7 of 10 active EoE trials reach primary completion in 2026

ClinicalTrials.gov API v2, pulled 17 Oct 2026: active interventional Phase 1–3 trials in eosinophilic esophagitis, all sponsor classes (n = 10), ordered by primary completion. ✓ = actual date, est. = estimated; a red outline marks an estimate not verified in over a year. Scroll sideways on small screens.

The 15 questions

Ranked by stakes, centrality, reach, frequency and data fit.

Each use case ships with an executive brief, a detailed dossier and a recipe that builds the board in one click.

  • BD-01
    #4

    Deal timing intelligence

    Spot assets approaching Phase 2/3 completion — the optimal window for partnership talks.

    For: BD / Alliance Management Lead
    TimelineTornado diagramFunnel chart
  • BD-11N
    #5

    Burden-adjusted whitespace / true unmet-need mapping

    Find indications and regions where disease burden is high but late-stage trials and approved options are scarce.

    For: Corporate Strategy / BD Lead
    Quadrant mapBullseyeGrouped bar
  • BD-12N
    #7

    Patent-cliff / loss-of-exclusivity timing map

    Map when competitor products lose patent and regulatory exclusivity to time deals, launches and lifecycle moves.

    For: BD / Corporate Development Lead
    TimelineGrouped barCumulative curve
  • BD-13N
    #8

    Asset 360 diligence dossier (trials + IP + filings + approvals)

    Assemble an independent, all-source dossier on a target asset or company spanning trials, patents, financial filings and approvals.

    For: Corporate Development / Diligence Lead
    Ownership / corporate structure treeBullseyeGrouped bar
  • BD-02
    #12

    Due diligence support

    Pull a complete, independent view of a target company's clinical pipeline, including failures.

    For: Corporate Development / Diligence Lead
    Ownership / corporate structure treeBar / column chartTimeline
  • BD-03
    #13

    Asset scouting

    Identify early-stage assets in academic or small-company hands to in-license or acquire.

    For: Business Development / Search & Evaluation Lead
    Funnel chartTimelineQuadrant map
  • BD-04
    #14

    Competitive deal landscape

    Track when competitor sponsors start new trials in your target indication as a BD signal.

    For: Competitive Intelligence / BD Lead
    TimelineTornado diagramBullseye
  • BD-05
    #19

    White space opportunity mapping

    Find indications with high unmet need but few late-stage trials to target for deals.

    For: Corporate Strategy / BD Lead
    Quadrant mapGrouped barCumulative curve
  • BD-06
    #20

    Portfolio gap analysis

    Map your portfolio against the broader trial landscape to reveal coverage gaps.

    For: Portfolio Strategy / Corporate Development Lead
    Coverage / gap gridBullseyeTreemap
  • BD-14N
    #33

    Program-survival / financial-distress asset sourcing

    Flag clinically promising assets at sponsors showing financial distress as in-licensing or acquisition opportunities.

    For: BD / Search & Evaluation Lead
    TimelineLine chartGrouped bar
  • BD-07
    #35

    Investor & board reporting

    Export aggregated trial-activity trends to support strategy presentations on opportunity size.

    For: Corporate Strategy / IR Lead
    KPI / metric snapshot panelBullet chartTimeline
  • BD-15N
    #36

    Upstream funding-flow scouting (pre-trial signal)

    Surface promising science via grant funding before it reaches the trial registries.

    For: BD / External Innovation Lead
    TimelineFunnel chartGrouped bar
  • BD-08
    #63

    Platform technology validation

    Assess whether a modality being considered for licensing has broad clinical applicability.

    For: BD / Technical Diligence Lead
    Funnel chartGrouped barCumulative curve
  • BD-09
    #76

    Partnership identification

    Find consortium-funded programs where co-development partnerships could be structured.

    For: BD / Alliance Management Lead
    Funnel chartTimelineGrouped bar
  • BD-10
    #77

    Geographic expansion planning

    Identify regions where a target asset has been clinically validated to guide territory negotiations.

    For: BD / Licensing Territory Lead
    Choropleth mapQuadrant mapDiverging bar chart
Try it

Ask the registry a bd & licensing question.

Ask the registryAI-assisted

AI reads your question into filters; every number comes straight from the ClinicalTrials.gov API. Don't enter personal or confidential information.

Bring one bd & licensing question to a pilot.

Eight weeks, one programme, success criteria agreed up front.

Plan a pilot